See All Slides - tctmd.com

Slides

Presentation TCT 2014

Heparins Crossover In Percutaneous Coronary Interventions: Is It A Real Issue With Increasing Rate Of Transradial Procedures?

Presenter: Stefano Rigattieri

September 16, 2014

Presentation TCT 2014

24h Ambulatory Blood Pressure (ABPM) Change After Using The New Symplicity Spyral Renal Sympathetic Denervation Device In Patients With Resistant Hypertension ? First Results Fr___

Presenter: Alexander Plehn

September 16, 2014

Presentation TCT 2014

Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Presenter: Saibal Kar

September 16, 2014

Presentation TCT 2014

Coronary Plaque Characterisation by Optical Coherence Tomography: An Inter-observer Analysis

Presenter: Catherine Jaworski

September 16, 2014

Presentation TCT 2014

Cost Comparisons of Invasive and Non-Invasive Diagnostic Evaluations for Patients with Suspected In-Stent Restenosis Following Implant of Metallic Stents and Bioresorbable___

Presenter: James Min

September 16, 2014

Presentation TCT 2014

3D Transesophageal Echocardiography provides optimal real-time guidance for off-pump, transapical implantation of artificial chordae tendineae_ An imaging study_

Presenter: Kestutis Rucinskas

September 16, 2014

Presentation TCT 2014

Novel Patient-based Finite Element Simulation Framework To Evaluate Fatigue Resistance Of Coronary Stent Design

Presenter: Peter Mortier

September 16, 2014

Presentation TCT 2014

Regular Drug-Eluting Stent Versus Dedicated Bifurcation Sirolimus-Eluting BiOSS LIM® Stent In Coronary Bifurcation Treatment ? Randomized POLBOS II Study_

Presenter: Jacek Bil

September 16, 2014

Presentation TCT 2014

The clinical efficacy of thrombus aspiration on five-year clinical outcomes in patients with ST-segment elevation acute myocardial infarction undergoing percutaneous coronary___

Presenter: HIroki Watanabe

September 16, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Advertisement

Slides

Heparins Crossover In Percutaneous Coronary Interventions: Is It A Real Issue With Increasing Rate Of Transradial Procedures?

24h Ambulatory Blood Pressure (ABPM) Change After Using The New Symplicity Spyral Renal Sympathetic Denervation Device In Patients With Resistant Hypertension ? First Results Fr___

Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Coronary Plaque Characterisation by Optical Coherence Tomography: An Inter-observer Analysis

Cost Comparisons of Invasive and Non-Invasive Diagnostic Evaluations for Patients with Suspected In-Stent Restenosis Following Implant of Metallic Stents and Bioresorbable___

3D Transesophageal Echocardiography provides optimal real-time guidance for off-pump, transapical implantation of artificial chordae tendineae_ An imaging study_

Novel Patient-based Finite Element Simulation Framework To Evaluate Fatigue Resistance Of Coronary Stent Design

Regular Drug-Eluting Stent Versus Dedicated Bifurcation Sirolimus-Eluting BiOSS LIM® Stent In Coronary Bifurcation Treatment ? Randomized POLBOS II Study_

The clinical efficacy of thrombus aspiration on five-year clinical outcomes in patients with ST-segment elevation acute myocardial infarction undergoing percutaneous coronary___

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content